arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Ardent Health, Inc.

ARDT

$15.90 ▲ +2.90 (+22.31%) at close

4 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Ardent Health, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.2B

Dividend Yield —

Revenue Growth 6.0% ↘

Op. Margin —

ROIC —

FCF / Share $3.34 ↗

Trailing P/E 16.6x

Price / Book 1.8x

FCF Yield 21.0%

Debt / Equity 0.87

info Valuation on last close. End-of-day price, Nov 5, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$6.32B

↑ +6.0% —

Net Income Profit after all expenses

$135.81M

↓ -35.4% —

FCF / Share Free cash flow per share

$3.34

↑ +40.5% —

Long-Term Debt Long-term obligations

$1.12B

— +0.2% —

Health Breakdown

Profitability ↓

Returns ↑

Financial Health ↓

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	6.0% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-25%)	10.3% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+29%)	5.5% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-32%)	—
EPS Growth YoY (%)	-39.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	269.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-71.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-35.4% Weak ↓ Weak Declining Year-over-year change in net income	290.2% Excellent Excellent Year-over-year change in net income	-71.5% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	40.5% Excellent Excellent Year-over-year change in free cash flow	35.3% Excellent Excellent Year-over-year change in free cash flow	N/M	—
Revenue CAGR 3Y (%)	7.2% Fair Fair Compound annual revenue growth over 3 years	—	—	—
EPS CAGR 3Y (%)	-13.8% Weak Weak Compound annual EPS growth over 3 years	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	19.6% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	17.4% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	2.1% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-82%)	3.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-71%)	1.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-92%)	3.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-69%)
FCF Margin (%) (%)	7.4% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	5.3% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	4.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-0.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	3.46x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.50x Good ↓ Good Declining Free cash flow relative to reported net income Optimal: > 1x	4.11x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	-0.20x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Common Equity (%) (%)	10.5% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-30%)	18.6% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+24%)	8.0% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-46%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	0.87x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+44%)	0.98x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+64%)	1.74x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+190%)	—
Net Debt (USD)	$406.36M	$557.29M	$730.68M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$44.93	$45.05	$42.89	$40.67
Basic EPS, GAAP (USD)	$0.96	$1.59	$0.43	$1.50
Free Cash Flow per Share (USD)	$3.34	$2.38	$1.76	$-0.30
Book Value per Share (USD)	$9.01	$7.93	$5.32	—
Tangible Book Value per Share (USD)	$2.86	$1.96	$-1.38	—
Basic Weighted Avg Shares (shares)	140.76M	132.44M	126.12M	126.12M

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$1.01B	$887.33M	$623.98M	—
LT Debt (USD)	$1.12B	$1.11B	$1.17B	—
Total Equity (USD)	$1.29B	$1.13B	$670.90M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$6.32B	$5.97B	$5.41B	$5.13B
Depreciation Expense (USD)	$155.70M	$146.29M	$140.84M	$138.17M
Net Income, GAAP (USD)	$135.81M	$210.34M	$53.90M	$188.91M
Operating Cash Flow (USD)	$470.51M	$315.03M	$221.70M	$-38.36M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 4 years · 14 quarters

Ardent Health, Inc.

Analytical Summary

4-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare ARDT with peers